公开(公告)号：US20170029506A1

公开(公告)日：2017-02-02

申请号：US15302927

申请日：2015-04-10

Applicant: Stichting VUmc

Inventor： Johannes Jelle VAN DER VLIET ,  Renée Cornelia Gerarda DE BRUIN ,  Tanja Denise DE GRUIJL ,  Hendrik Marinus Willem VERHEUL

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  C07K2317/21 ,  C07K2317/22 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/75 ,  C07K2317/76

Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.

Abstract translation: 本发明涉及医学领域，涉及免疫学，特别涉及人Vγ9Vδ2T细胞受体结合免疫球蛋白分子。 人Vγ9Vδ2T细胞受体结合免疫球蛋白分子特别用于医学治疗和/或用于与人Vγ9Vδ2T细胞的测定中，其中可以调节人Vγ9Vδ2T细胞。

公开(公告)号：WO2020022891A3

公开(公告)日：2020-01-30

申请号：PCT/NL2019/050480

申请日：2019-07-24

Applicant: STICHTING VUMC ,  ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM

Inventor： BRUNDEL, Bianca Johanna Josephina Maria ,  WIERSMA, Marit ,  DE GROOT, Natasja Mireille Silvia ,  ZHANG, Deli

IPC: A61P9/06 ,  C12Q1/68

Abstract: The invention relates to methods of typing an individual as suffering from, or at risk of suffering from, atrial fibrillation, comprising the steps of providing a bodily fluid from said individual and quantifying a biomarker in said bodily fluid. The invention further relates to methods for assigning standard-of-care therapy to an individual that is typed as suffering from, or at risk of suffering from, atrial fibrillation, according to the methods of typing of the invention, and to a standard- of-care therapy for use in a method of treating an individual that is typed as suffering from, or at risk of suffering from, atrial fibrillation, according to the methods of the invention.

公开(公告)号：WO2019220369A2

公开(公告)日：2019-11-21

申请号：PCT/IB2019/054034

申请日：2019-05-15

Applicant: JANSSEN BIOTECH, INC. ,  STICHTING VUMC

Inventor： ADAMS, Homer ,  GAUDET, Francois ,  FRERICHS, Kris ,  VAN DE DONK, Niels ,  VERLEIJ, Christie C.P.M.

IPC: C07K16/28

Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.

公开(公告)号：WO2018217087A1

公开(公告)日：2018-11-29

申请号：PCT/NL2018/050341

申请日：2018-05-23

Applicant: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS ,  STICHTING VUMC

Inventor： BOSCH, Linda Janna Willemien ,  DE WIT, Meike ,  PINTO MORAIS DE CARVALHO, Beatriz ,  FIJNEMAN, Remondus Johannes Adriaan ,  JIMENEZ, Cornelia Ramona ,  MEIJER, Gerrit Albert ,  COUPE, Veerle Marleen Herman

IPC: G01N33/574

Abstract: The invention relates to methods for typing a sample of an individual suffering from a colorectal cancer, or suspected of suffering therefrom. A preferred sample is stool. The invention further relates to methods for determining a level of expression of at least two extracted protein expression molecules in stool,, based on the quantified reaction products, and to methods of assigning treatment to an individual that was typed as suffering from colorectal cancer according to the invention.

公开(公告)号：WO2018111099A8

公开(公告)日：2018-06-21

申请号：PCT/NL2017/050831

申请日：2017-12-12

Applicant: STICHTING VUMC ,  STICHTING VU

Inventor： SMIT, August Benjamin ,  HOOZEMANS, Jeroen Joseph Maria ,  HONDIUS, David Carolus ,  KWAKKEL, Johanna Maria

IPC: A61K51/10 ,  G01N33/50 ,  G01N33/68

Abstract: The invention relates to biomarkers and diagnostic methods for determining the presence and/or risk of cerebral amyloid angiopathy (CAA) as well as to methods for screening for treatments for CAA.

公开(公告)号：WO2018026283A1

公开(公告)日：2018-02-08

申请号：PCT/NL2017/050526

申请日：2017-08-04

Applicant: STICHTING VUMC

Inventor： GRIFFIOEN , Arjan Willem ,  HUIJBERS, Else ,  NOWAK-SLIWINSKA, Patrycja

IPC: C07K14/245 ,  C12N15/09 ,  C12N15/62

Abstract: The invention is in the field of medicine. More specifically, it is in the field of diagnosing tumor angiogenesis status and in the field of medical treatment of a subject who is suffering, suspected to suffer, or might suffer from a tumor in the future. In particular, the invention relates to a fusion polypeptide comprising a foreign antigen and a self antigen, wherein said foreign antigen consists of a polypeptide comprising an amino acid sequence of at least 12-15 amino acid residues, 12-24% of which residues are hydrophilic, bulky amino acid residues selected from the group consisting of histidine, glutamate, arginine, glutamine, aspartic acid and/or lysine.

Abstract translation:

本发明属于医学领域。 更具体地说，它处于诊断肿瘤血管生成状态以及将来患有，怀疑患有或可能患有肿瘤的受试者的医学治疗领域。 特别地，本发明涉及包含外源抗原和自身抗原的融合多肽，其中所述外源抗原由包含至少12-15个氨基酸残基的氨基酸序列的多肽组成，其中12-24％的残基是 选自组氨酸，谷氨酸，精氨酸，谷氨酰胺，天冬氨酸和/或赖氨酸的亲水性大体积氨基酸残基。

公开(公告)号：WO2022204129A8

公开(公告)日：2022-09-29

申请号：PCT/US2022/021325

申请日：2022-03-22

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES ,  STICHTING VUMC

Inventor： SADELAIN, Michel ,  THEMELI, Maria ,  SJÖSTRAND, Maria ,  KATSAROU, Afroditi

IPC: C07K16/30 ,  C07K16/40 ,  A61P35/00 ,  A61P35/02 ,  A61K35/17 ,  A61P37/02 ,  A61K2039/5156 ,  A61K39/001112 ,  A61K39/001117 ,  A61K39/001129 ,  C07K16/2803 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2317/622 ,  C07K2319/03

Abstract: The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.

公开(公告)号：WO2022204129A1

公开(公告)日：2022-09-29

申请号：PCT/US2022/021325

申请日：2022-03-22

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  MEMORIAL HOSPITAL FOR CANER AND ALLIED DISEASES ,  STICHTING VUMC

Inventor： SADELAIN, Michel ,  THEMELI, Maria ,  SJÖSTRAND, Maria ,  KATSAROU, Afroditi

IPC: C07K16/30 ,  C07K16/40 ,  A61P35/00 ,  A61P35/02 ,  A61K35/17 ,  A61P37/02

Abstract: The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.

公开(公告)号：WO2020197399A1

公开(公告)日：2020-10-01

申请号：PCT/NL2020/050216

申请日：2020-03-27

Applicant: STICHTING VUMC

Inventor： TIJMS, Betty Marije ,  VISSER, Pieter Jelle ,  BLENNOW, Kaj Ingemar ,  ZETTERBERG, John Henrik ,  GOBOM, Per Johan

IPC: G01N33/68

Abstract: The invention relates to method for typing a sample of an individual suffering from, or is suspected to suffer from, a progressive neurodegenerative disease. The invention further relates to methods for assigning a treatment of the individual, based on said typing.

公开(公告)号：WO2020159368A1

公开(公告)日：2020-08-06

申请号：PCT/NL2020/050051

申请日：2020-01-30

Applicant: LAVA THERAPEUTICS B.V. ,  STICHTING VUmc

Inventor： VAN DER VLIET, Johannes Jelle ,  DE WEERDT, Iris ,  DE GRUIJL, Tanja Denise ,  PARREN, Paul ,  KATER, Aron Philip ,  SCHEFFER, George Lodewijk

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.